Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 79

1.

Influence of SREBP-2 and SCAP gene polymorphisms on lipid-lowering response to atorvastatin in a cohort of Chilean subjects with Amerindian background.

Lagos J, Zambrano T, Rosales A, Salazar LA.

Mol Diagn Ther. 2014 Aug;18(4):435-43. doi: 10.1007/s40291-014-0094-3.

PMID:
24615250
2.

Atorvastatin effects on SREBF1a and SCAP gene expression in mononuclear cells and its relation with lowering-lipids response.

Arazi SS, Genvigir FD, Willrich MA, Hirata MH, Dorea EL, Bernik M, Hirata RD.

Clin Chim Acta. 2008 Jul 17;393(2):119-24. doi: 10.1016/j.cca.2008.03.031. Epub 2008 Apr 8.

PMID:
18435918
3.

APOE polymorphisms contribute to reduced atorvastatin response in Chilean Amerindian subjects.

Lagos J, Zambrano T, Rosales A, Salazar LA.

Int J Mol Sci. 2015 Apr 9;16(4):7890-9. doi: 10.3390/ijms16047890.

4.

High baseline serum total and LDL cholesterol levels are associated with MDR1 haplotypes in Brazilian hypercholesterolemic individuals of European descent.

Rodrigues AC, Rebecchi IM, Bertolami MC, Faludi AA, Hirata MH, Hirata RD.

Braz J Med Biol Res. 2005 Sep;38(9):1389-97. Epub 2005 Aug 26. Erratum in: Braz J Med Biol Res. 2007 Nov;40(11):1577.

5.

Influence of SCARB1 polymorphisms on serum lipids of hypercholesterolemic individuals treated with atorvastatin.

Cerda A, Genvigir FD, Arazi SS, Hirata MH, Dorea EL, Bernik MM, Bertolami MC, Faludi AA, Hirata RD.

Clin Chim Acta. 2010 May 2;411(9-10):631-7. doi: 10.1016/j.cca.2010.01.002. Epub 2010 Jan 11.

PMID:
20064494
6.

Do MDR1 and SLCO1B1 polymorphisms influence the therapeutic response to atorvastatin? A study on a cohort of Egyptian patients with hypercholesterolemia.

Shabana MF, Mishriki AA, Issac MS, Bakhoum SW.

Mol Diagn Ther. 2013 Oct;17(5):299-309. doi: 10.1007/s40291-013-0038-3.

PMID:
23677857
7.

No impact of SLCO1B1 521T>C, 388A>G and 411G>A polymorphisms on response to statin therapy in the Greek population.

Giannakopoulou E, Ragia G, Kolovou V, Tavridou A, Tselepis AD, Elisaf M, Kolovou G, Manolopoulos VG.

Mol Biol Rep. 2014 Jul;41(7):4631-8. doi: 10.1007/s11033-014-3334-z. Epub 2014 Mar 26.

PMID:
24668570
8.

Influence of PCSK9 polymorphisms on plasma lipids and response to atorvastatin treatment in Brazilian subjects.

Anderson JM, Cerda A, Hirata MH, Rodrigues AC, Dorea EL, Bernik MM, Bertolami MC, Faludi AA, Hirata RD.

J Clin Lipidol. 2014 May-Jun;8(3):256-64. doi: 10.1016/j.jacl.2014.02.008. Epub 2014 Mar 5.

PMID:
24793346
9.

APOA1 polymorphisms are associated with variations in serum triglyceride concentrations in hypercholesterolemic individuals.

Sorkin SC, Forestiero FJ, Hirata MH, Guzmán EC, Cavalli SA, Bertolami MC, Salazar LA, Hirata RD.

Clin Chem Lab Med. 2005;43(12):1339-45.

PMID:
16309370
10.

Identification of pharmacogenetic predictors of lipid-lowering response to atorvastatin in Chilean subjects with hypercholesterolemia.

Rosales A, Alvear M, Cuevas A, Saavedra N, Zambrano T, Salazar LA.

Clin Chim Acta. 2012 Feb 18;413(3-4):495-501. doi: 10.1016/j.cca.2011.11.003. Epub 2011 Nov 19.

PMID:
22120734
11.

SLCO1B1 c.388A>G Polymorphism Is Associated with HDL-C Levels in Response to Atorvastatin in Chilean Individuals.

Prado Y, Saavedra N, Zambrano T, Lagos J, Rosales A, Salazar LA.

Int J Mol Sci. 2015 Aug 31;16(9):20609-19. doi: 10.3390/ijms160920609.

12.

Pharmacogenetics of OATP transporters reveals that SLCO1B1 c.388A>G variant is determinant of increased atorvastatin response.

Rodrigues AC, Perin PM, Purim SG, Silbiger VN, Genvigir FD, Willrich MA, Arazi SS, Luchessi AD, Hirata MH, Bernik MM, Dorea EL, Santos C, Faludi AA, Bertolami MC, Salas A, Freire A, Lareu MV, Phillips C, Porras-Hurtado L, Fondevila M, Carracedo A, Hirata RD.

Int J Mol Sci. 2011;12(9):5815-27. doi: 10.3390/ijms12095815. Epub 2011 Sep 9.

13.

The discrete and combined effect of SREBP-2 and SCAP isoforms in the control of plasma lipids among familial hypercholesterolaemia patients.

Durst R, Jansen A, Erez G, Bravdo R, Butbul E, Ben Avi L, Shpitzen S, Lotan C, Leitersdorf E, Defesche J, Friedlander Y, Meiner V, Miserez AR.

Atherosclerosis. 2006 Dec;189(2):443-50. Epub 2006 Feb 8.

PMID:
16466730
14.

Atorvastatin and hormone therapy effects on APOE mRNA expression in hypercholesterolemic postmenopausal women.

Issa MH, Cerda A, Genvigir FD, Cavalli SA, Bertolami MC, Faludi AA, Hirata MH, Hirata RD.

J Steroid Biochem Mol Biol. 2012 Feb;128(3-5):139-44. doi: 10.1016/j.jsbmb.2011.11.001. Epub 2011 Nov 7.

15.

Efficacy of ezetimibe is not related to NPC1L1 gene polymorphisms in a pilot study of Chilean hypercholesterolemic subjects.

Zambrano T, Saavedra N, Lanas F, Caamaño J, Salazar LA.

Mol Diagn Ther. 2015 Feb;19(1):45-52. doi: 10.1007/s40291-014-0128-x.

PMID:
25589339
16.

Apolipoprotein E mRNA expression in mononuclear cells from normolipidemic and hypercholesterolemic individuals treated with atorvastatin.

Cerda A, Genvigir FD, Willrich MA, Arazi SS, Bernik MM, Dorea EL, Bertolami MC, Faludi AA, Hirata MH, Hirata RD.

Lipids Health Dis. 2011 Nov 10;10:206. doi: 10.1186/1476-511X-10-206.

17.

CYP3A53A allele is associated with reduced lowering-lipid response to atorvastatin in individuals with hypercholesterolemia.

Willrich MA, Hirata MH, Genvigir FD, Arazi SS, Rebecchi IM, Rodrigues AC, Bernik MM, Dorea EL, Bertolami MC, Faludi AA, Hirata RD.

Clin Chim Acta. 2008 Dec;398(1-2):15-20. doi: 10.1016/j.cca.2008.07.032. Epub 2008 Aug 5.

PMID:
18727922
18.

Interactions between CYP7A1 A-204C and ABCG8 C1199A polymorphisms on lipid lowering with atorvastatin.

Wei KK, Zhang LR, Zhang Y, Hu XJ.

J Clin Pharm Ther. 2011 Dec;36(6):725-33. doi: 10.1111/j.1365-2710.2010.01227.x. Epub 2010 Dec 3.

PMID:
21128988
19.

Antioxidant effect of atorvastatin is independent of PON1 gene T(-107)C, Q192R and L55M polymorphisms in hypercholesterolaemic patients.

Sardo MA, Campo S, Bonaiuto M, Bonaiuto A, Saitta C, Trimarchi G, Castaldo M, Bitto A, Cinquegrani M, Saitta A.

Curr Med Res Opin. 2005 May;21(5):777-84.

PMID:
15969877
20.

3'UTR/T polymorphism of lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1) is associated with modified anti-platelet activity of atorvastatin in hypercholesterolemic subjects.

Puccetti L, Pasqui AL, Pastorelli M, Ciani F, Palazzuoli A, Gioffrè W, Auteri A, Bruni F.

Atherosclerosis. 2005 Dec;183(2):322-8. Epub 2005 Apr 22.

PMID:
16285995

Supplemental Content

Support Center